---
title: "野村将石药集团的目标价从 9.11 港元调整至 12.04 港元，并维持买入评级"
description: "野村将石药集团的目标价从 9.11 港元上调至 12.04 港元，维持 “买入” 评级"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/276056763.md"
published_at: "2026-02-16T12:30:47.000Z"
---

# 野村将石药集团的目标价从 9.11 港元调整至 12.04 港元，并维持买入评级

> 野村将石药集团的目标价从 9.11 港元上调至 12.04 港元，维持 “买入” 评级

### Related Stocks

- [01093.HK - 石药集团](https://longbridge.com/zh-CN/quote/01093.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-CN/news/276035104.md) |
| CSPC Pharma Unit Files Application with HKEX for Proposed H-Share Listing | CSPC Pharma Unit Files Application with HKEX for Proposed H-Share Listing | [Link](https://longbridge.com/zh-CN/news/269327436.md) |
| Essent Group raises dividend by 12.9% to 0.35 | Essent Group raises dividend by 12.9% to 0.35 | [Link](https://longbridge.com/zh-CN/news/275908049.md) |
| CSPC Pharma Gets China Nod for Multiple Drug Trials | CSPC Pharma Gets China Nod for Multiple Drug Trials | [Link](https://longbridge.com/zh-CN/news/270994613.md) |
| CICC Sticks to Its Buy Rating for CSPC Pharmaceutical Group (CHJTF) | CICC has reaffirmed its Buy rating for CSPC Pharmaceutical Group (CHJTF) with a price target of HK$12.00. Additionally,  | [Link](https://longbridge.com/zh-CN/news/274393834.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。